Hyperfine Crecimiento futuro
Future controles de criterios 2/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Hyperfine de 3.2% y 28.8% respectivamente, mientras que el BPA crecerá en un 12.4% al año.
Información clave
3.2%
Tasa de crecimiento de los beneficios
12.45%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Medical Equipment | 16.0% |
| Tasa de crecimiento de los ingresos | 28.8% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 29 Apr 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización del análisis • Apr 30
HYPR: European Approvals And New Financing Will Support Future Upside Potential
Analysts have raised their price target on Hyperfine by $0.30, citing updated fair value assumptions of $1.60 per share that reflect adjusted expectations for revenue growth, profit margins, discount rate, and a higher future P/E multiple. What's in the News Received CE Marking and UK Conformity Assessment approval for the next generation Swoop portable MRI system and the latest Optive AI software, allowing commercialization across Europe and the UK.
Actualización del análisis • Apr 16
HYPR: European Approvals And Clinical Evidence Will Drive Future Upside
Analysts now set a $2.05 price target for Hyperfine, unchanged from before, reflecting updated views on discount rate, profit margin, and expected future P/E, without a shift in the overall valuation level. What's in the News Hyperfine received CE Marking and UKCA approval for its next generation Swoop system and latest Optive AI software, clearing the way for commercialization of its portable MRI technology across Europe and the UK and broadening its international reach in brain imaging (Product related announcement).Actualización del análisis • Apr 01
HYPR: Growing Clinical Evidence In Stroke And Outpatient Care Will Drive Upside
Analysts have lifted their Hyperfine price target from $1.65 to $2.05, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E that adjust the stock's risk and earnings outlook in their models. What’s in the News Entered a new loan and security agreement with Horizon Technology Finance Corporation for a senior secured term loan facility of up to US$40 million, including an initial US$15 million draw and the option to access an additional US$25 million through December 31, 2027, with interest only payments through March 18, 2031 (Key Developments).Actualización del análisis • Mar 18
HYPR: Expanding Stroke And Outpatient Evidence Will Support Future Upside
Analysts have maintained their $1.65 price target for Hyperfine, citing largely unchanged assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E as the basis for this view. What's in the News The largest data set to date for stroke detection with the Swoop system reported strong evidence supporting AI powered portable MRI for ischemic stroke detection in emergency and other clinical settings.Actualización del análisis • Mar 04
HYPR: Expanding Clinical Evidence And New Trials Will Support Future Upside
Analysts have kept their price target for Hyperfine steady at $1.65, with small tweaks to assumptions such as a slightly higher discount rate, modestly better projected profit margin, and a somewhat lower future P/E helping to support the unchanged view. What's in the News The largest stroke detection data set to date for the Swoop system was reported.Actualización del análisis • Feb 18
HYPR: India Approval And Clinical Data Will Support Future Upside Potential
Analysts have modestly revised their price target for Hyperfine to $1.30, reflecting updated assumptions around a slightly lower discount rate, marginally higher revenue growth and profit margin expectations, and a small adjustment to the projected future P/E multiple. What's in the News The largest stroke detection data set for the Swoop system was published in Stroke: Vascular and Interventional Neurology.Actualización del análisis • Feb 04
HYPR: Growing Clinical Evidence And New Approvals Will Support Upside
Analysts have kept their price target for Hyperfine unchanged at $1.65, reflecting only minor adjustments to underlying model inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The largest-to-date stroke detection study with the Swoop system reported strong sensitivity and specificity for ischemic lesion detection, including very small strokes, with shorter scan times and improved brain image quality in emergency settings (Stroke: Vascular and Interventional Neurology).Actualización del análisis • Jan 21
HYPR: Expanded Clinical Use And New Regulatory Wins Will Drive Upside
Analysts have modestly adjusted their price target for Hyperfine to US$1.65, reflecting tweaks to key inputs such as a slightly lower discount rate, marginally softer revenue growth and profit margin assumptions, and a higher future P/E expectation. What's in the News Hyperfine enrolled the first patient in the Contrast PMR study, a prospective multi center trial evaluating contrast enhanced ultra low field portable MRI to support a potential future FDA submission to expand Swoop system use with gadolinium based contrast agents.Artículo de análisis • Jan 15
Revenues Tell The Story For Hyperfine, Inc. (NASDAQ:HYPR) As Its Stock Soars 34%
Hyperfine, Inc. ( NASDAQ:HYPR ) shareholders are no doubt pleased to see that the share price has bounced 34% in the...Actualización del análisis • Jan 06
HYPR: India Approval Will Support Future Upside Potential
Analysts have modestly adjusted their price target on Hyperfine, reflecting small tweaks to the discount rate, revenue growth and future P/E assumptions while keeping fair value steady at US$1.30. What's in the News Hyperfine received regulatory approval in India for its Swoop portable MRI system from the Central Drugs Standard Control Organization, allowing commercialization across the country through a distribution partnership with Radiosurgery Global Ltd.Actualización del análisis • Dec 18
HYPR: India Approval And New MRI Software Will Drive Strong Upside Potential
Analysts have raised their price target on Hyperfine from approximately $0.85 to $1.30 per share, citing stronger projected revenue growth, slightly improved profit margins, and a higher expected future P E multiple, despite a modest uptick in the assumed discount rate. What's in the News Hyperfine received regulatory approval from India's Central Drugs Standard Control Organization to commercialize its Swoop portable MRI system nationally, opening access to advanced brain imaging in a large, under-served market (Key Developments).Actualización del análisis • Dec 04
HYPR: Expanded Clinical Use And Subscription Platform Will Drive Future Upside
Analysts have maintained their price target for Hyperfine at 1.65 dollars, reflecting largely unchanged views on the company. Slight improvements in discount rate and profit margin estimates are offset by a marginally lower future earnings multiple.Actualización del análisis • Nov 20
HYPR: Expanding Clinical Applications Will Drive 2025 Revenue Acceleration
Narrative Update on Hyperfine: Analyst Price Target Revision Analysts have slightly reduced their price target for Hyperfine from $1.70 to $1.65, citing updated forecasts for revenue growth and profit margins as key factors behind the adjustment. What's in the News Management expects fourth quarter 2025 revenue to be approximately $5 to $6 million, which would represent sequential and year-over-year quarterly growth of 60% and 137%, respectively.Actualización del análisis • Nov 05
HYPR: International Approvals And Expanded Use Will Drive Upside Momentum
Narrative Update on Hyperfine Analyst Price Target Analysts have maintained their fair value estimate for Hyperfine at $1.70. They cite largely unchanged growth projections along with only small adjustments in profit margin and discount rate assumptions.Actualización del análisis • Oct 21
Analysts Lift Hyperfine Price Target Amid Positive Studies and Stronger Revenue Growth Forecast
Analysts have raised their price target for Hyperfine from $1.42 to $1.70. They cite higher projected revenue growth and a slightly lower discount rate as reasons for a more bullish outlook.Artículo de análisis • Oct 07
Hyperfine, Inc. (NASDAQ:HYPR) Looks Just Right With A 30% Price Jump
Despite an already strong run, Hyperfine, Inc. ( NASDAQ:HYPR ) shares have been powering on, with a gain of 30% in the...Actualización del análisis • Aug 29
FDA Clearances And Demographics Will Create Opportunity Despite Valuation Risks
The significant upward revision in Hyperfine’s consensus analyst price target is primarily driven by a notable increase in its forecasted Future P/E, with fair value rising from $1.19 to $1.42. What's in the News Hyperfine provided 2025 earnings guidance, expecting 10%–20% revenue growth over 2024.Actualización del análisis • Aug 15
FDA Clearances And Demographics Will Create Opportunity Despite Valuation Risks
With both Net Profit Margin and Future P/E essentially unchanged, analysts have maintained their consensus price target for Hyperfine at $1.19. What's in the News Hyperfine received FDA clearance for its next-generation portable MRI system powered by Optive AI software, delivering significant improvements in image quality, speed, and usability, targeting broader adoption across diverse care settings, including hospitals, neurology offices, and remote environments.Artículo de análisis • Jul 23
Market Participants Recognise Hyperfine, Inc.'s (NASDAQ:HYPR) Revenues Pushing Shares 46% Higher
Hyperfine, Inc. ( NASDAQ:HYPR ) shares have had a really impressive month, gaining 46% after a shaky period beforehand...Artículo de análisis • May 16
Here's Why Hyperfine (NASDAQ:HYPR) Must Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Nuevo análisis • Apr 09
2025 Swoop Software Releases Will Boost Healthcare Imaging Adoption
Launching AI-powered software and expanding into neurology offices will likely enhance market penetration and diversify revenue streams.Artículo de análisis • Mar 22
What You Can Learn From Hyperfine, Inc.'s (NASDAQ:HYPR) P/S After Its 28% Share Price Crash
Hyperfine, Inc. ( NASDAQ:HYPR ) shares have had a horrible month, losing 28% after a relatively good period beforehand...Artículo de análisis • Feb 05
Hyperfine, Inc. (NASDAQ:HYPR) Looks Just Right With A 25% Price Jump
Hyperfine, Inc. ( NASDAQ:HYPR ) shares have continued their recent momentum with a 25% gain in the last month alone...Artículo de análisis • Nov 15
Analysts Are Updating Their Hyperfine, Inc. (NASDAQ:HYPR) Estimates After Its Third-Quarter Results
Shareholders might have noticed that Hyperfine, Inc. ( NASDAQ:HYPR ) filed its third-quarter result this time last...Seeking Alpha • Oct 06
Hyperfine appoints Maria Sainz as President, CEO
Hyperfine (NASDAQ:HYPR) has named medical device industry veteran Maria Sainz as President and CEO of Hyperfine, effective Oct. 24, 2022. Scott Huennekens, who currently serves as interim President and CEO, will stay on as Executive Chairperson of the Board. HYPR -5.79% premarket to $1.14.Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 35 | -33 | N/A | N/A | 1 |
| 12/31/2027 | 26 | -33 | N/A | N/A | 2 |
| 12/31/2026 | 20 | -34 | N/A | N/A | 3 |
| 12/31/2025 | 14 | -36 | -29 | -28 | N/A |
| 9/30/2025 | 11 | -40 | -32 | -31 | N/A |
| 6/30/2025 | 11 | -39 | -35 | -34 | N/A |
| 3/31/2025 | 12 | -40 | -36 | -36 | N/A |
| 12/31/2024 | 13 | -41 | -39 | -39 | N/A |
| 9/30/2024 | 13 | -41 | -41 | -40 | N/A |
| 6/30/2024 | 12 | -41 | -41 | -41 | N/A |
| 3/31/2024 | 12 | -42 | -42 | -41 | N/A |
| 12/31/2023 | 11 | -44 | -43 | -42 | N/A |
| 9/30/2023 | 10 | -47 | -48 | -47 | N/A |
| 6/30/2023 | 10 | -49 | -52 | -51 | N/A |
| 3/31/2023 | 8 | -62 | -59 | -59 | N/A |
| 12/31/2022 | 7 | -73 | -73 | -72 | N/A |
| 9/30/2022 | 6 | -86 | -77 | -75 | N/A |
| 6/30/2022 | 4 | -89 | -75 | -72 | N/A |
| 3/31/2022 | 3 | -81 | -70 | -67 | N/A |
| 12/31/2021 | 1 | -65 | -50 | -47 | N/A |
| 9/30/2021 | 1 | -46 | -39 | -37 | N/A |
| 6/30/2021 | 1 | -35 | -34 | -32 | N/A |
| 3/31/2021 | 1 | -26 | -26 | -25 | N/A |
| 12/31/2020 | 0 | -23 | -23 | -22 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que HYPR siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que HYPR siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que HYPR siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (28.8% al año) de HYPR crezcan más rápidamente que los del mercado US (11.6% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (28.8% al año) de HYPR crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de HYPR se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/12 04:32 |
| Precio de las acciones al final del día | 2026/05/12 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Hyperfine, Inc. está cubierta por 4 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Yuan Zhi | B. Riley Securities, Inc. |
| Marie Thibault | BTIG |
| Vijay Kumar | Evercore ISI |